ee , Poly(ADP-ribosyl)ation is a po$t,translational modification catalyzed by the en~me family of poly(ADP-ribose) polymerases (PARPs). PARPs exhibit pleiot(opic; cellular functions ranging from maintenance of genomic stabUityand chromatin remodeling to regulation of eel! death, thereby rendering PARP homologues promising tar~ets In cancertherapy.Depending on the molecular status of.~ ca:ocercett,low~molecutar weight PARPe inhibitors can (t)eltherbe used'asmonotherapeutic agents followingtheconcept~f synthetic lethality or (11) to support classical chemotherapy orradiothEi~apy.The rationales are the foUowing:(t)in cancers with selective defects in homologous recombination repair, inactivation of PARPs directly causes cell death. In cancer treatment, this phenomenon can be employedtospecificaUy target tlimor cells while sparing nonmalignant tissue. (ii)PARP inhibitorsClln also be used to sensitize cells t!lcytotoxic DNA-damaging treatments. as some PARPs actively participate ingenornicmaii'itenance. Apart from that, PARPhihibietors possess antiangiogenlcfuoctions, thuse opening up a further opti?llto irihibit tUrn?t growth. In view eof the above, a number of high-potencyPARP.inhibitors have been developed during thetast deecadeandare currently evaluated as cancer therapeutics in cUnical trials bysllveral teading pharmaceutical companies.
lapping DNA repair mechanisms exist: 06-methyl guanine methyltransferase (MGMT), base excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR) and DNA double-strand break (DSB) repair including the subpathways homologous recombination (HR) and nonhomologous end joining (NHEJ).2 Because of the action of turn or suppressor mechanisms such as DNA repair and cell cycle control, acquired mutations are usually rare. However, if tumor suppressor mechanisms fail this can cause high mutation rates and sustained genomic instability, both of which are known to drive the evolution of cancers. On the other hand, specific DNA repair mechanisms still need to be functional within tumor cells to ensure cellular survival. I Moreover, the functionality of specific DNA repair pathways represents an important mechanism of cancer resistance to DNA-damaging chemo-and radiotherapy. Thus, paradOxically, targeting tumor suppressor mechanisms such as DNA repair is an attractive approach in cancer therapy to sensitize tumor cells to cytotoxic treatments and to overcome acquired resistance to these treatments. 3 Consequently, several DNA repair inhibitors are currently being developed as anticancer drugs, and among the most advanced are inhibitors of poly(ADPribosyl)ation. Poly(ADP-ribosyl)ation is a post-translational modification catalyzed by enzymes of the family of poly(ADP-ribose) polymerases (PARPs). PARPs use NADT as a substrate to form the linear or branched biopolymer poly(ADP-ribose) (PAR) and the by-product nicotinamide (Fig. 1) . 4 While PARPs can covalently modify themselves (automodification) or other proteins (heteromodification), PAR can also bind noncovalently to numerous proteins via at least three glycohydrolase (PARG) are indicated by arrows. So far, PARP activity has been unequivocally identified for PARP1, PARP2, PARP4 and tankyrases 1 and 22 Purthermore, the MMR proteins MSH2 and MSH6 bind PAR in a noncovalent manner. s PARP1 also functions as a regulator of telomere length 23 • 24 and is involved in organizing the spindle apparatus. 25 • 26 Importantly, PARP1 also regulates the nuclear localization and activity of the tumor suppressor gene pS3. 27 ,28
In view of the above, PARP1 is considered a general caretaker of the genome. 29 Accordingly, P ARP I-deficient mice and cells are hypersensitive to IR and alkylating agents. 30 The fact that PARP1-deficient mice are prone to induced tumor formation and show an increased age-dependent spontaneous tumor load suggests a role for PARP1 as a tumor suppressor gene. 31 , 32 In this regard, it is interesting to mention that the formation of some human cancers has been linked to a hypomorphic single nucleotide polymorphism in the gene encoding PARPI, leading to the amino acid replacement V762A. 33 Moreover, PARP1 expression is upregulated in various types of human cancers, and this has been linked to resistance of cancer cells to genotoxic treatment.,l3-.l7 In stark contrast, PARPl activity was also discussed as a tumor promoter in a mouse model of skin carcinogenesis, which may be related to its function as an inducer of cell death and tissue inflammation in specific conditions. 38 We recently generated a mouse model with ectopic expression of human P ARP-l, which lead to premature development of inflammation-related chronic diseases and further 253 supported the view of a complex and double-edged role of PARP-1 during carcinogenesis. 39 ,4o Thus, the age-related tumor-spectrum of those mice was shifted showing lower incidence of sarcomas, but increased incidence of carcinomas, which may be related to the development of inflammatory diseases.
Apart from P ARP I, P ARP2 is the only other P ARP family member known to be activated by binding to DNA structures. It accounts for most of the residual nuclear PAR formation upon DNA damage and physically and functionally interacts with PARPl. PARPI and PARP2 exhibit, at least in part, redundant functions. This is supported by partially overlapping phenotypes of the corresponding knock-out mice and by the fact that double deficiency results in embryonic lethality in the mouse. 41 ,42 Recently, functions of PARP2 independent of PARPl, such as in genomic maintenance, gene transcription, and T-cell development, were reported. 41 Although PARP2-deficient mice do not show enhanced spontaneous tumor development, there is rapid development of spontaneous T -cell lymphomas in a pS3-deficient background, suggesting that P ARP2 may also act as a tumor suppressor gene in specific genetic constellations.
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PARP3 mainly resides in the nucleus;!1 where it mayexhibit mono(ADP-ribosyl)ation activity.45 During cell division, P ARP3 localizes to centrosomes and is involved in the regulation of Gl/S cell cycle progression. 46 Although a direct role of PARP3 in DNA repair is still a matter of debate,45 it is striking that the major interaction partners of P ARP3 are involved in the NHEJ pathway. Moreover, PARP3 immunoprecipitates with DNA ligase III and is able to activate PARPI in the absence of DNA, which links it to BER.44 PARP4 also known as Vault PARP (VPARP) is part of the cytoplasmic vault ribonucleoprotein complex, which has been implicated in multidrug resistance. VP ARP has been localized to the nuclear pore and the mitotic spindle and exhibits poly(ADP-ribosyl)ation activity.47 VPARP-deficient mice show an increase in carcinogen-induced colon and lung tumor incidence as well as reduced tumor latency:18 P ARPSa and P ARPSb, better known as tankyrases (TNKS) I and 2, exhibit poly(ADP-ribosyl)ation activity. They localize to multiple subcellular sites including cytoplasmic membrane compartments, telomeres and spindle poles. While TNKS1 was reported to act as a positive regulator of telomere length and is required to resolve sister telomeres during mitosis, the role of TNKS2 in telomere length regulation remains to be determined. 49 Apart from its role in telomere regulation, TNKSI was also implicated in GLUT4 vesicle trafficking: 19 Both tankyrases seem to exhibit at least in part redundant functions, since Tnksl and Tnks2 single knock-out mice are viable, whereas double deficiency is embryonically letha1. 50 Expression analyses showed that tankyrase expression levels are upregulated in a variety of human cancers, indicating a direct role of tankyrases in carcinogenesis. 49 PARPIO is localized in the nucleus and the cytoplasm and was reported to possess mono(ADP-ribosyl)ation activity. It was identified as a c-MYC interacting protein, suppressing cellular transformation induced by c-MYC and E1A protein. 51 ,52 PARP9, PARP14 and PARP15 belong to the subfamily of macro-P ARPs. While P ARP9 is catalytically inactive, P ARP 14 possesses mono(ADP-ribosyl)ation activity and PARP15 either mono-or poly(ADP-ribosyl)ation activity.52,53 They are localized mainly in the nucleus and contain macrodomains. In general, macrodomains are highly conserved structures that are often involved in the setting of the chromatin status. Macro-PARPs in particular are involved in the transcriptional regulation in response to cytokines and have been linked to carcinogenesis. 54 Because of their differential expression in Bcell lymphomas, they were also designated as B aggressive lymphoma (BAL) proteins. P ARP9 was originally identified in a genome-wide search for risk-related genes in diffuse large B-cell lymphoma and its expression was significantly increased in chemoresistant tumors. 53 In summary, several P ARP family members play active roles in carcinogenesis, which renders them interesting drug targets for cancer therapy. Such an approach gains even further attraction by the findings that at least short term absence of P ARP function seems to have only minor physiological consequences in the absence of DNA damage and genomic instability. Interestingly, in a preclinical mouse model also long-term treatment with a highly potent PARP inhibitor (AZD2281) did not result in any obvious signs of toxicity.55 Consequently, various phase I and II clinical trials are currently underway to evaluate the use of P ARP inhibitors in treatment of a variety of tumors including breast cancers, ovarian cancers, prostate cancer, colorectal cancer, gastric cancer, cancer of the small intestine, hepatocellular carcinomas (HCCs), sarcomas, lymphomas, melanomas, pancreatic neoplasms and glioblastomas. At present one inhibitor, i.e., BSI-201 (Sanofi-Aventis), reached phase III clinical trials for breast cancer and squamous cell lung cancer therapy in combination with gemcitabine/carboplatin (http:// c1inicaltrials.gov) .
In the paragraphs below, we discuss the underlying molecular mechanisms of how P ARP inhibition (P ARPi) mediates tumor cell death (Fig. 2) . Review articles with a more clinical focus of PARPi have been published recently.50.57
Chemistry and Pharmacology of PARP Inhibitors
Most P ARP inhibitors are competitive with the substrate NAD+ and thus interfere with its binding to the enzyme's active site, which is highly conserved between different P ARP homologues. Interestingly, nicotinamide itself, i.e., the byproduct of PAR formation, acts as a natural weak inhibitor of PARP activity. Molecular modeling and X-ray crystallography revealed that the amide of the nicotinamide forms three crucial hydrogen bonds with PARP1 at the hydroxyl group of Ser904 and the amide backbone of Gly863. Furthermore, the pyridyl ring interacts via a 1t-1t stacking with Tyr907. 58 ,59 Based on a good understanding of the structure-activity relationship, a significant increase in potency of PARP inhibitors was achieved during the last decades. Likewise, their bioavailability was considerably improved. 60 Based on their chemical structure, the following classes of P ARP inhibitors can be distinguished: In principle, there are two ration ales for the usage of PARP inhibitors in cancer therapy: (i) use as stand-alone drugs for tumors with a specific genetic make-up, following the "synthetic lethality" concept and (ii) use in combination with DNA-damaging treatments such as chemo-and radiotherapy.
PARP Inhibitors in Monotherapy
Tumor-dependent DNA repair deficiencies represent an attractive target in cancer therapy by following the concept of synthetic lethality.67 Two genes are synthetically lethal if loss of function of either gene alone is compatible with cell survival, but mutation or inactivation of both cause cell death. As a result, targeting a gene that is synthetic lethal to a cancer-relevant mutation should kill only malignant cells and spare normal cells.
GB The first proof-of-principle of this novel approach in a clinical setting was achieved with PARP inhibitors in BRCA-deficient mammary carcinoma cells. The tumor suppressors BRCA1 and BRCA2 participate in HR and mitotic control. 69 Germline mutations in one of the BRCAl or the BRCA2 alleles predispose to the development of several cancers, including breast, ovarian and prostate cancer. Malignant cells in patients carrying a heterozygous loss-of-function BRCA mutation typically display loss of heterozygosity. This results in HR deficiency, which causes genetic instability and drives carcinogenesis. 70 The loss of HR repair is not shared with normal cells and can be exploited by P ARPi to induce selective tumor cytotoxicity. Mechanistically, cells with inhibited P ARP activity may acquire more unrepaired SSBs and stalled or collapsed replication forks caused by endogenous DNA-damaging events. Replication forks contain several proteins such as helicases and polymerases, forming the so-called replisome. Usually progression of the replication fork continues until it encounters a replication fork barrier such as DNA-protein complexes or SSBs. In this case the replicative helicase progresses much more slowly, so that the fork is "stalled." If this goes along with the disassembly of the replisome the fork "collapses" and a DSBs is formed. 71 Usually DSBs ariSing from collapsed replication forks are repaired by RAD51-dependent HR; however, in cells with loss of function of BRCA1 or BRCA2, HR is defective and repair of these breaks by alternative error-prone DSB repair mechanisms would cause genomic instability, leading to cell death. Overall, there is ample evidence supporting such a model with regard to PARPi: Loss of PARP1 function can induce the formation of nuclear RAD51 foci as well as sister chromatid exchange in BRCA-proficient cells, indicating the repair of DSBs. In contrast, no RAD51 foci were formed in BRCA-deficient cells. Instead, PARP inhibitor-treated BRCA-deficient cells showed more chromatid aberrations compared to wt cells. Furthermore, PARPi induced the formation of y-H2A.x foci, which indicate sites of DNA damage. 72 • 73 Such a phenotype suggests failure of DSB repair by conservative RADS1-dependent sister-chromatid recombination and activation of alternative error-prone pathways such as NHEJ. 72 . 74 Interestingly, PARP1 itself participates in the reactivation of stalled replication forks.
7s It binds to and is activated at stalled replication forks and mediates the recruitment of Mrell to promote replication fork restart after release from replication blocks. 76 , 77 On the other hand, PARPi could also have an effect on the repair of occurring DSBs by alternative mechanisms, e.g., via its involvement in NHEJ. 78 RNAi experiments supported the view that PARP1 rather than PARP2 is responsible for the repair of toxic recombinogenic lesions that spontaneously occur in human cells.
n .
73 Thus, depletion of P ARP2 and BRCA2 had no effect on clonogenic survival of the cells, and depletion of PARP2 in PARPl and BRCA-2-depleted cells did not result in additional toxicity.
The concept of synthetic lethality represents one of the few examples, where the mutation that caused carcinogenesis can be exploited for targeted cancer therapy. Recently, a phase I clinical trial with Olaparib in patients enriched in carriers of BRCA mutations was conducted?9 P ARPi was achieved successfully in peripheral blood lymphocytes, hair follicle cells and tumor tissue. Carriers of BRCA mutations did not show an increased risk of adverse effects. In line with the cell culture data mentioned above, P ARPi in patients' hair follicle cells was rapidly associated with downstream induction of DSBs. 79 Although most patients with BRCA mutations showed a response in this and another phase II study, not all BR CA mutation carrying patients did SO.79, 80 The authors hypothesized that this may have resulted from preexisting genetic resistance; thus, it was shown that secondary BRCA2 mutations may restore BRCA function and HR, thereby causing resistance to PARPi. SI , 82 Moreover, the effectiveness of PARP-inhibitor-dependent cell death in BRCA deficiency depended on the use of highly potent P ARP inhibitors. 73 ,83,84 Although the inhibitors used in the studies described here were reported to exhibit selectivity for PARP1 and PARP2 with 1-3 orders of magnitude over PARP3, vPARP and tankyrase,73 specificities for other PARPs were not tested. Therefore, the specificity of the synthetic lethal mechanism with regard to PARP1 inhibition is not entirely clear. In this regard, it is interesting to mention that synthetic lethal interactions also exist in cells deficient for both TNKS1 and BRCA. 85 In future studies, it will be interesting to expand this concept to cancers with other defects in HR, such as loss of function of RADS1, ATM, ATR and CHKl and CHK2, as well as components of the Fanconi's anemia repair pathway. First preclinical data already showed promising results. Thus, ATM-deficient cells were shown to be sensitive to PARPi. 86 Moreover, P ARPi sensitizes A TM -deficient cells to DNAdamaging agents?O These data are consistent with the finding that PARPi leads to the activation of ATM, which then induces the subsequent HR repair. 86 Mutations in the A TM gene were detected in T-cell leukemia, mantle-cell lymphoma and chronic B-lymphocytic leukemia, rendering tumors with such mutations ideal candidates for PARPi therapy.s6 In addition, deficiency of the PTEN tumor suppressor gene causes a HR defect. Consequently, PTEN deficiency sensitized tumor cells to potent PARP inhibitors.s7 Viewed together, there is a considerable potential to extend monotherapy with PARP inhibitors to a larger group of patients with general defects in HR. 88 ,89 Thus, tumors showing "BRCAness" may represent another promising target for P ARPi. For instance, some sporadic breast or ovarian cancers show epigenetic inactivation of BRCAl.
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PARP Inhibitors in Combination Therapy
Many cancer therapies act by causing DNA damage, which, if unrepaired, triggers cell death. Consequently, DNA repair mechanisms may render cancer cells resistant to chemotherapy or radiotherapy. Several PARPs, especially PARP1 and PARP2, actively participate in several DNA repair mechanisms, in particular in the repair of SSBs. Therefore, P ARPi sensitizes tumor cells to cytotoxic DNA-damaging agents and IR, thereby improving the therapeutic index of those therapies. Consequently, several preclinical and clinical studies using P ARP inhibitors in combination with cytotoxic agents including monofunctional alkylating agents, such as temozolomide, topoisomerase-I poisons, such as topotecan, and DNA-crosslinking agents, such as cisplatin, have been conducted. The data showed that P ARPi sensitizes malignant cells to all of these agents (summarized in Table 1 ). Likewise, P ARPi sensitizes tumor cells to IR, in vitro and in vivo.
PARP inhibitors as chemosensitizers
The DNA-methylating agent temozolomide (TMZ) is rapidly converted into an active intermediate, i.e., S-(3-methyltriazen-lyl)imidazol-4-carboxamide. TMZ can cross the blood brain barrier efficiently and exhibits limited bone marrow toxicity. TMZ is used as a stand-alone drug or in combination with IR in the therapy of central nervous system malignancies, such as glioblastoma multiforme and melanomas. TMZ acts via the addition of methyl adducts to three main positions in nucleobases, i.e., N 7 -methylguanine (~70% of adducts), 06-methylguanine (~S% of adducts) and N 3 -methyladenine (~9% of adducts). 91 The mechanism of action of TMZ-induced cytotoxicity is mainly through the formation of 06-methylguanine. Thus, during replication 06-methylguanine incorrectly pairs with thymine, leading to the induction of MMR. However, the repair of the mismatched base mainly leads to the reinsertion of thymine, resulting in futile cycles of repetitive DNA repair, finally causing DSB formation and apoptosis. 91 Resistance to TMZ is frequently observed by two different mechanisms: (i) Upregulation of MGMT activity and subsequent efficient repair of 06-methylguanine. 92 (ii) Development of MMR deficiency: In the absence of MMR the cell is able to survive despite the presence of 0 methylguanine, since MMR is required for the induction of DNA-strand breaks after the formation of 06-methylguanine. P ARP activity in patients' lymphocytes is increased at 4h after TMZ administration due to DNA damage induction. As P ARPi restrains BER, other lesions of methylpurines which are usually efficiently repaired by BER become lethal via the induction of apoptosis.
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Consequently, PARPi following TMZ treatment resulted in increased peak levels of DNAstrand breaks and the persistence of N-methylpurines, most likely increasing cytotoxicity.93 Presumably, potentiation of TMZ cytotoxicity by P ARPi requires the conversion of SSBs to DSBs in actively dividing cells passing S-phase, as shown recently in an analogous cell culture model using P ARPi in combination with the DNA methylating agent methyl methanesulfonate (MMS).94 Therefore, in general, a PARP inhibitor that has a long half-life or can accumulate for a long period of time in tumors is preferred for optimal potentiation of TMZ. 22 Moreover, PARP-l was reported to bind to DNA damages induced by platinum compounds, suggesting a direct role of P ARP-l in the repair of such damages.
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Accordingly, several studies suggest that P ARPi potentiates the effect of platinum compounds. Thus, it was shown that P ARPi increases the cytotoxicity of platinum complexes in cisplatin-resistant ovarian tumor cells. 11 3 Another study showed selective synergy between P ARPi and cisplatin in BRCA2-deficient mammary tumor cells. l14 Moreover, combination of PARPi (AZD2281) with platinum compounds increased the survival in a genetically engineered mouse model of hereditary breast cancer. S5 Nevertheless, most tumors in this study could not be eradicated with P ARPi/ platinum combination schedules indicating the existence or development of resistant tumor cells. s5 Also in another study cotreatment of spontaneously occurring tumors with P ARPi (AZD2281) and carboplatin in a tissue-specific BRCA and pS3-deficient mouse model showed no advantage over carboplatin monotherapy. However, if PARPi was continued as a monotherapy, the time to tumor relapse or death was significantly increased, indicating that such a therapy schedule represents a beneficial treatment option. llS The latter study also suggested that effectiveness of P ARPi and platinum compounds are both dependent on functional HR indicating that the mechanism of platinum-induced DNA damage response is not fully understood yet. Contrasting reports about pharmacotoxicology of platinum/P ARPi cotreatment exist in the literature: while increased nephrotoxicity of cisplatin in combination with PARPi (AZD2281) was observed in one study,S5 cotreatment of cisplatin with P ARP inhibitors (3AB, BGP-lS) was reported to attenuate cisplatin-induced nephrotoxicity in other studies.116.117 Consistent with the notion that activation of P ARP is implicated in the etiology of cisplatin-induced toxicity, PAR synthesis was found to be enhanced upon cisplatin treatment in renal proximal tubular cells. Jl7 This aspect calls for further research, as it represents a potential mechanism of lowering cisplatin-induced toxicity. Currently, phase I and II clinical trials are conducted using PARP inhibitors in combination with platinum compounds against "triple negative" and BRCA-mutated breast cancers, ovarian cancers as well as advanced solid tumors. 56 Moreover, the PARP inhibitor BSI-20l (Sanofi-Aventis) is in phase III clinical trials for breast cancer and squamous cell lung cancer therapy in combination with gemcitabine/carboplatin. (http://clinicaltrials.gov).
Nuclear DNA topoisomerase 1 (Topo!) introduces a transient SSB by forming a covalent DNA-Topo! complex, which allows for the rotation of DNA around the intact strand and relaxation of supercoiling. Thereafter, religation of the SSB restores the DNA integrity and the enzyme diSSOCiates from the DNA.
lI8 Topo! is inhibited by the alkaloid camptothecin, which is the parent compound of the anticancer agents irinotecan and topotecan, currently used to treat ovarian, cervical and small cell lung cancer. Camptothecins induce formation of a stable DNA-Topol complex preventing religation of the DNA-strand break and dissociation of the enzyme. I IS This leads to increased numbers of SSBs and stalled replication forks, which require PARP-mediated repair. Although the DNA-Topo! complex does per se not induce cell death, it may become lethal during replication, when DSBs are formed by collapse of stalled replication forks during S-phase.
ll9 Of note, PARPl itself directly interacts with and induces the activity of Topo!. Therefore, combination treatment of Topo! inhibitors with PARP inhibitors may enhance tumor cell cytotoxicity by counteracting Topol activity and favoring the accumulation of SSBs and unresolved replication forks.120-122 Consequently, PARPi in combination with topotecan treatment is effective in different cell lines of lung, colon, ovary and breast cancers as well as in human neuroblastoma and colon adenocarcinoma xenografts.104.108.123 Currently, phase I and II clinical trials are conducted with P ARP inhibitors in combination with Topo! inhibitors against ovarian cancer, advanced colorectal cancer and other advanced solid tumors.
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Topoisomerase 2 (Top02) can resolve topological problems in DNA structures by introducing a transient DSB, and it is involved in several nuclear functions, including chromosome segregation, DNA replication and chromosome organization. Inhibition of Top02 activity and induction of enzymemediated DNA damage is an effective strategy for chemotherapy. 124 However, in contrast to sensitization of Topol, data of P ARPi in combination with Top02 inhibitors are less conclusive. P ARPi did not increase cytotoxicity caused by the Top02 inhibitor etoposide. Etoposide did not activate PARP even at concentrations that caused significant levels of apoptosis. m Moreover, the classical Top02 inhibitor amsacrine (m-AMSA) affected mouse cells independently of their PARPl status. However, studies on triazoloacridones yielded contrasting results. These compounds were also reported to be inhibitors of Top02 and were shown to exhibit very strong cytotoxic activity toward malignant cells in vitro and a strong cytostatic effect against solid tumors in nude mice. Within this class of inhibitors, the potent Top02 inhibitor C-130S strongly affected proliferation of PARPI-deficient fibroblasts, whereas the action of less active compound C-lS33 toward normal and PARPl-deficient cells was comparable. While C-1305 had only weak effects on DNA damage and apoptosis, it strongly affected cell-cycle progression in normal and PARPI-mutant cells and arrested both cell types in G2-M phase. This G2-M arrest was greatly prolonged in PARPI-deficient cells as compared with wild-type fibroblasts. However, other studies showed that metabolites of triazoloacridones covalently bind to DNA, which may explain at least in part the conflicting results with classical Top02 inhibitors and could provide an alternative mechanism of interference with P ARP function in the case of triazoloacridones usage. 126
PARP inhibitors as radiosensitizers
Ionizing radiation mediates cytotoxicity via induction of DNA damage, i.e., SSBs and DSBs at a ratio of~2S:I. 127 SSBs are mainly repaired by BER, in which PARPI and P ARP2 exhibit crucial functions as mentioned above. 128 In analogy to camptothecin toxicity, SSBs induced by IR are presumably not cytotoxic per se, but may become lethal during replication, when DSB are formed by replication fork collapse. 119 This view is compatible with findings showing that P ARPi increased replication-dependent DSBs and delayed repair of radiation-induced DNA breaks associated with yH2A.x and RADSI foci, which are indicators of HR repair. 129.1 30 Furthermore, radiosensitizing effects of PARPi are pronounced in dividing cells, but abolished in growtharrested cells.129-131 PARPi potentiated IR-induced cytotoxicity in PARPI-proficient, but not in PARPI-deficient cells, indicating that PARPI is the main contributor to IR-insensitivity. IJ2 However, P ARPi and ablation produce different outcomes concerning radiosensitivity, i.e., P ARPi radiosensitizes cells specifically in S-phase, whereas silencing of PARPI renders cells hypersensitive to IR regardless of cell cycle status, demonstrating that PARPI has functions either dependent on its enzymatic activity or not. 130 . 133 A further level of compexity is added by the finding that PARPI is an essential mediator of IR-induced NF-kappaB activation, which in turn is an important mediator of resistance to IR. Thus, PARPi sensitized p6S-proficient but not the p6S-deficient cells to IR. Therefore, potentiation of IR-induced cytotoxicity by a potent PARP inhibitor (AG14361) was thought to be mediated by inhibition of NF-kappaB activation. 134 The observation that P ARPi is equally effective to radiosensitize cells in normoxic or hypoxic conditions may be clinically relevant, since a hypoxic environment can drive the selection of aggressive turn or cell phenotypes through increased genomic instability and downregulation of DNA repair. Hypoxic cells are about 3-fold more radioresistant than normoxic cells, and intratumoral hypoxia has been described as a significant source of treatment failure using radiotherapy. us Currently, P ARP inhibitors are evaluated as radiosensitizers in phase I and II clinical trials of treatment of head and neck cancers as well as CNS neoplasms. In this regard, it is interesting to note that glioblastoma cells are a rapidly dividing cell population within the nonreplicating tissue of the normal brain and are therefore an attractive target for P ARPi/IR combination therapy, especially in view of the fact that P ARPi potentiates the cytotoxicity of TMZ, which is often used in combination with radiation therapy.129
PARP Inhibitors as Antiangiogenic Agents
Usually, once a normal tissue is formed in the adult organism, the formation of new blood vessels is a tightly controlled mechanism. However, tumors depend on the establishment of microcirculation to grow beyond a few millimeters. Moreover, metastatic cells are only released into the circulation after the tumor established its own microcirculation. Different sequential steps are necessary for this kind of vasculogenesis. These processes are mediated by angiogenic factors. Therefore, targeting these factors for cancer therapy is currently under investigation. 136 A role of PARPI in angiogenesis has been reported previously.137 Thus, PARPi leads to a reduction of tumor vasculature and down regulation of the expression of genes involved in angiogenesis during skin carcinogenesis in mice. Differences in tumor-related gene expression, i.e., genes that are involved in inflammation and vasculogenesis, were also found between PARP inhibitor-treated HCC and control xenografts. Therefore, PARPi appeared to be capable of controlling HCC growth and preventing tumor vasculogenesis by regulating the activation of different genes involved in tumor progression. 138 In particular, P ARPi has been demonstrated to reduce the induction of hypoxia-inducible factor-lex (HIFlex). HIF is a transcription factor that binds to hypoxiaresponse elements and activates various genes involved in angiogenesis, energy metabolism, cell proliferation and apoptosis. 137.139-142 Additionally, PARPI-depleted melanoma xenografts displayed reduced expression of the angiogenesis marker PECAM-I/CD31 and the proinflammatory mediators TNF-Q( and GITR. 99 Furthermore, P ARPi at concentrations devoid of cytotoxiC effects abrogated migration in response to vascular endothelial growth factor or placenta growth factor, inhibited formation of tubule-like networks, and impaired angiogenesis in vivo, which can be attributed at least in part to PARPl. 143 Although the role in tumor vasculogenesis is far from understood, the current preclinical results suggest a supportive effect of PARPi in cancer therapy by counteracting tumor-neovasculogenesis.
Concluding Remarks
Even though the use of P ARPi in cancer therapy has received much attention in recent years, some issues remain to be addressed carefully in the near future:
An important question is the issue of long-term safety. The use of P ARP inhibitors was suggested as a prophylactic treatment for individuals with heterozygous BRCA mutations.
144 However, such proposals should be considered with great caution: A caveat in the systemic long-term treatment with P ARP inhibitors is the impairment of DNA repair and genomic stability in normal cells, which may lead to secondary tumors at later age. The fact that research on homologue-specific P ARP inhibitors is still at an early stage and that Parp1l2 as well as Tnks-1I2 double knock-outs are not viable makes it necessary to carefully balance for risk and benefit of PARPi therapy. Moreover, it needs to be monitored if the unusual mechanism of PARPi by BSI-20l, i.e., via an irreversible, covalent protein modification, affects long-term toxicity during clinical usage differently compared to classical competitive P ARP inhibitors. Another caveat that should be considered is the genetic status of a tumor, as P ARPi can attenuate the cytotoxic effects of cisplatin against RB-deficient tumors. Mechanistically, this outcome was explained by the finding that usually DNA damage-induced death of RB-deficient cells was primarily necrotic which is dependent on PARP overactivation. [45 However, due to the promising preclinical and clinical data of P ARP inhibitor usage in monoor combination therapy, the P ARP inhibitors treatment regimens against manifest cancer appear justifiable at the current stage.
The route of cell death that is pursued upon P ARPi is another field of research that awaits further clarification: Usually, DNA-damaging agents and IR mediate their lethal effects via enhanced apoptosis, necrosis, mitotic catastrophe and tumor cell senescence.146 Additional P ARPi seems to switch the route of cell death from necrosis to apoptosis, because DNA damage-induced necrosis often depends on P ARP activity. [13.147 If such a switch in the terminal phenotype of tumor cells has also consequences on the effectiveness of the eradication of the tumors, e.g., enhanced stimulation of tumor-killing immune cells, needs to be determined in future studies. Moreover, enhanced autophagy and senescence have been described recently as alternative terminal phenotypes of tumor cells upon P ARPi in combination with radiotherapy.146.148 It will be interesting to see if these terminal phenotypes also play a significant role in other treatment regimens.
A further issue that has been analyzed only sporadically includes PARP-inhibitor-dependent off-target effects. Thus, theoretically, P ARP inhibitors may also interfere with References NAD+-dependent enzymes other than PARPs, such as mono-ADP-ribosyltransferases or sirtuins and may result in considerable off-target effects.6o Only a few PARP inhibitors, including ABT-888, have been tested for off-target effects on sirtuins and have been shown to be inactive. 63 Although genetic and RNAi approaches suggest that sensitization and cytotoxic effects of P ARPi depend predominantly on PARPl, the question if other PARP homologues also contribute to the antitumor effects is largely unsolved. Therefore, development of homologue-specific P ARP inhibitors is another priority for future research. Progress in this field may also provide the basis for further improvement in P ARPi treatment in order to reduce off-target effects; however, as mentioned before the field of homologue-specific P ARPi is still in its infancy. Perkins et al., for example, discovered compounds of the quinazolinone and phthalazinone structure with modest selectivity for PARPl and PARP2, respectively.149 Distinct binding modes necessary for discrimination between Iigands and each homologue were identified, enabling the synthesis of inhibitors with some selectivity for PARPl and PARP2, respectively.63.1S0.151 Moreover, the PARP inhibitor BYK204l65 demonstrated lOO-fold selectivity for PARPl over PARP2 in vitro, with IC50 values for PARPl in the nanomolar range.
152 Such results demonstrate the feasibility of designing P ARP-homologue-selective Iigands. Furthermore, the recent structural analyses of PARP2 and PARP3 in complex with different P ARP inhibitors should be instrumental for the design of homologue-specific inhibitors. 15. 1 In summary, since the discovery of poly(ADP-ribosyl)ation about half a century ago, the field made significant progress in the understanding of the biochemistry and the cellular function of this post-translational modification. Although there are still a lot of open questions to address, especially regarding the exact cellular functions of the individual P ARPs, it is quite obvious that several P ARPs exhibit important roles in the process of carcinogenesis. This knowledge can be and is being exploited for establishing new rational treatment modalities for cancer.
